Skip to content
Announcement:

Latest Publication: Read our teams’ latest paper in Antibiotics, showing reduced nephrotoxicity of a novel formulation of polymyxin B compared to the clinical formulation using a validated primary human proximal tubule cell model.

5th Gene Therapy for Opthalmic Disorders Summit

Date

10th September 2024 - 12 September, 2024

Location

Boston, MA

This extensive three-day event will tackle obstacles spanning preclinical and clinical development. From engineering AAVs and innovating vectors for enhanced delivery and transduction to specific target cells, to confirming suitable clinical endpoints that demonstrate efficacy, all facets will be covered.

 

Drawing in teams from R&Dpreclinical, and clinical development sectors of prominent biotech and pharmaceutical companies, this gathering offers a chance to gain insights into successful strategies shared by those with first-hand experience in developing ocular gene therapies.

 

Share on social media:

Don't miss out on our latest innovations: follow us on Linkedin

Get our latest updates straight to your inbox